HDAC9 and neoplasm: By examining newly reported inhibitors through this structural lens, we highlight not only how modifications in each domain affect potency and HDAC isoform preference, but also how certain strategies address persistent challenges such as metabolic instability, off-target toxicity, and poor tumor selectivity.